Sugi Predict

Sugi Predict / Targets / TGM3

TGM3

Protein-glutamine gamma-glutamyltransferase E · Q08188 · TGM3 on Sugi Atlas →

2,780 patent compounds predicted against TGM3, 1,972 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1869225 SCHEMBL1869225 0.53 3/20
SCHEMBL1869036 SCHEMBL1869036 1.00 2/20
SCHEMBL1869426 SCHEMBL1869426 1.00 2/20
SCHEMBL1870446 SCHEMBL1870446 0.77 2/20
SCHEMBL1870745 SCHEMBL1870745 0.75 2/20
SCHEMBL1871762 SCHEMBL1871762 0.74 2/20
SCHEMBL1867871 SCHEMBL1867871 0.73 2/20
SCHEMBL1871580 SCHEMBL1871580 0.73 2/20
SCHEMBL1869912 SCHEMBL1869912 0.71 2/20
SCHEMBL1877756 SCHEMBL1877756 0.71 2/20
SCHEMBL1874491 SCHEMBL1874491 0.70 2/20
SCHEMBL1865035 SCHEMBL1865035 0.70 2/20
SCHEMBL1877511 SCHEMBL1877511 0.70 2/20
SCHEMBL1871768 SCHEMBL1871768 0.69 2/20
SCHEMBL1876408 SCHEMBL1876408 0.69 2/20
SCHEMBL1873503 SCHEMBL1873503 0.68 2/20
SCHEMBL1876148 SCHEMBL1876148 0.68 2/20
SCHEMBL1872505 SCHEMBL1872505 0.67 2/20
SCHEMBL1884721 SCHEMBL1884721 0.67 2/20
SCHEMBL1871756 SCHEMBL1871756 0.67 2/20

Clinical trials — most relevant to TGM3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori PHASE4UNKNOWN
Sildenafil for Liver Fibrosis in Adolescents and Adults After Fontan Operation PHASE4UNKNOWN
Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients PHASE3UNKNOWN
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus PHASE3COMPLETED
SGM-101 in Locally Advanced and Recurrent Rectal Cancer PHASE2/PHASE3UNKNOWN
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma PHASE3RECRUITING
SGM-101 in Colorectal Brain Metastases. PHASE2UNKNOWN
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis PHASE2COMPLETED
SGM-101 in Colorectal Lung Metastases PHASE2UNKNOWN
Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer PHASE2UNKNOWN
A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis PHASE2UNKNOWN
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer PHASE1/PHASE2COMPLETED
Gene Therapy For Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease PHASE1/PHASE2COMPLETED
Study of STG-001 in Subjects With Stargardt Disease PHASE2COMPLETED
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease PHASE1COMPLETED
Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis. PHASE1COMPLETED
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease PHASE1RECRUITING
Phase I Study of GST-HG151 Tablets in Healthy Volunteers PHASE1UNKNOWN
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease PHASE1COMPLETED
A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers PHASE1COMPLETED
Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure nanUNKNOWN
Study of PHN131 in Healthy Volunteers nanCOMPLETED
Causes, Complications and Outcomes of Severe Acute Liver Disease Cases Admitted to Intensive Care Units nanUNKNOWN
Safety Study of Black Cohosh Use by Postmenopausal Women on the Liver nanCOMPLETED
a Single-arm, Single-center, Open Clinical Study nanRECRUITING
Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol nanCOMPLETED
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD) nanCOMPLETED
RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study nanRECRUITING
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule nanUNKNOWN
cACLD in Patients With Alcohol Use Disorder in the Hospital Detoxification Unit nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a TGM3 binder may also engage these)

ProteinNameSimilarity
A6QP57 — 1.000 A6QP57 →
Q08189 — 1.000 Q08189 →
D4A5U3 — 1.000 D4A5U3 →
O08619 — 0.992 O08619 →
P08587 — 0.990 P08587 →
P23606 — 0.990 P23606 →
Q01841 — 0.990 Q01841 →
P22758 — 0.989 P22758 →
P21981 — 0.988 P21981 →
P51176 — 0.988 P51176 →
F13A1 Coagulation factor XIII A chain 0.987 landscape →
Q9WVJ6 — 0.987 Q9WVJ6 →
Q9JLF6 — 0.987 Q9JLF6 →
Q05187 — 0.987 Q05187 →
P49221 — 0.986 P49221 →
Q8BH61 — 0.986 Q8BH61 →
P52181 — 0.985 P52181 →
Q9D7I9 — 0.985 Q9D7I9 →
Q9GLK0 — 0.985 Q9GLK0 →
Q8BZH1 — 0.985 Q8BZH1 →
TGM1 Protein-glutamine gamma-glutamyltransferase K 0.985 landscape →
Q5ZJM3 — 0.984 Q5ZJM3 →
P52183 — 0.982 P52183 →
O43548 — 0.981 O43548 →
Q96PF1 — 0.981 Q96PF1 →
TGM2 Protein-glutamine gamma-glutamyltransferase 0.981 landscape →
P49222 — 0.979 P49222 →
Q4R6F3 — 0.979 Q4R6F3 →
Q92178 — 0.977 Q92178 →
P50757 — 0.977 P50757 →